مقاله انگلیسی رایگان در مورد استنشاق دوز اندازه گیری شده فشرده دارو در درمان بیماری های تنفسی – الزویر ۲۰۱۸
مشخصات مقاله | |
انتشار | مقاله سال ۲۰۱۸ |
تعداد صفحات مقاله انگلیسی | ۸ صفحه |
هزینه | دانلود مقاله انگلیسی رایگان میباشد. |
منتشر شده در | نشریه الزویر |
نوع مقاله | ISI |
عنوان انگلیسی مقاله | Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases |
ترجمه عنوان مقاله | استنشاق دوز اندازه گیری شده فشرده برای داروهای چند دوزی در درمان بیماری های تنفسی |
فرمت مقاله انگلیسی | |
رشته های مرتبط | پزشکی |
گرایش های مرتبط | بیماری های ریوی |
مجله | پزشکی تنفسی – Respiratory Medicine |
دانشگاه | Pulmonary Research Institute of Southeast Michigan – USA |
کلمات کلیدی | داروهای استنشاقی، ارسال دارو، استنشاق دوز اندازه گیری شده فشرده، فرمول دارو |
کلمات کلیدی انگلیسی | Inhaled drugs, Drug delivery, Pressurized metered-dose inhalers, Drug formulation |
کد محصول | E6117 |
وضعیت ترجمه مقاله | ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید. |
دانلود رایگان مقاله | دانلود رایگان مقاله انگلیسی |
سفارش ترجمه این مقاله | سفارش ترجمه این مقاله |
بخشی از متن مقاله: |
۱٫ Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous diseases with multiple components, including chronic inflammation, airway obstruction, and airway hyperresponsiveness [1]. Numerous medications are available for asthma and COPD, most of which are administered by oral inhalation devices [2,3]. The first propellant-based, pressurized metered-dose inhalers (pMDIs) were developed in the mid-1950s [4,5], beginning an era of portable and compact modern inhalers with highly efficient aerosolization engines. Oral inhalation is the standard method of medication administration for patients with asthma [6] and COPD [7] as it achieves targeted drug delivery to the lungs. Direct administration to the airways has several advantages over systemic administration, including rapid delivery of low doses to the airways [3] and reduced potential for adverse events, as well as increased efficacy [8]. Asthma and COPD are distinct diseases with defined treatment paradigms and objectives, but are currently treated with many of the same classes of inhaled medications due to their overlapping disease features [2,7]. Moreover, both are chronic diseases that require continued maintenance therapies, often with escalating interventions [9,10]. Treatment escalation can involve administration of multiple drugs and may require use of multiple inhaler devices. The use of different drugs from different delivery systems can be confusing for patients, and potentially increase errors in inhaler technique. Thus, the availability of different fixed-dose combinations in a single inhaler device may be beneficial, allowing escalation or de-escalation without changing the inhaler device. Potential combinations include: (1) bronchodilator combinations (e.g., long-acting beta-agonist [LABA]/long-acting muscarinic antagonist [LAMA]) for patients with COPD; (2) an antiinflammatory drug plus a bronchodilator (e.g., inhaled corticosteroid [ICS]/LABA) for patients with asthma or COPD; or, although currently still in clinical development, (3) triple therapy (e.g., ICS/ LAMA/LABA) for patients with asthma or COPD. |